Phorbol Myristate Acetate Inhibits the Bradykinin-Induced L-Nitro-Arginine Insensitive Endothelium-Dependent Relaxation of Bovine Coronary Artery

Takeshi Obi, Fumio Suzuki and Akira Nishio*

Department of Veterinary Pharmacology, Faculty of Agriculture, Kagoshima University, Kagoshima 890, Japan

Received May 27, 1993 Accepted August 23, 1993

ABSTRACT—The effects of L-nitro-arginine (LNAG) and phorbol myristate acetate (PMA) were studied in bradykinin-induced relaxations in bovine coronary arteries. In the presence of indomethacin (10 μM), neither LNAG (100 μM) nor PMA (0.1 μM) inhibited the bradykinin-induced relaxations in coronary arterial rings contracted with prostaglandin F2α. However, simultaneous application of LNAG and PMA almost completely abolished the bradykinin-induced relaxation. In a sandwich-method, endothelium-intact coronary arteries (donor vessels) were treated with LNAG or with PMA for 30 min and then placed in close apposition to a denuded ring (assay vessel). Pretreatment of the donor vessels with LNAG, but not with PMA, almost completely abolished the bradykinin-induced relaxations in the assay vessel. In contrast, treatment of the assay vessel with PMA or with LNAG had no effect. These results suggest that bradykinin-induced endothelium-dependent relaxation of bovine coronary artery depends on both the release of nitric oxide and other endothelium-derived relaxing factor(s), which is an extremely labile substance(s), or a non-diffusible factor(s). PMA seems to inhibit the production and/or the release of the latter substance(s).

Keywords: Endothelium-dependent relaxation (bradykinin-induced), Coronary artery (bovine), L-Nitro-arginine, Nitric oxide, Phorbol myristate acetate

It has been shown that bradykinin induces endothelium-dependent relaxation of arteries isolated from a variety of species by releasing endothelium-derived relaxing factors (EDRFs) (1). It has been reported that one of the EDRFs is nitric oxide or a labile nitric oxide-containing substance (2, 3). However, recent studies indicated that nitric oxide does not account for all of the endothelium-dependent relaxations evoked by bradykinin (4, 5). In addition, bradykinin has been shown to induce endothelium-dependent hyperpolarization of porcine coronary arteries, which is probably due to the release of endothelium-derived hyperpolarizing factor (EDHF) (6–8).

In porcine coronary arteries, it has also been reported that nitric oxide probably does not play a major role in the bradykinin-induced endothelium-dependent relaxation (9, 10). Recently, we have also found that bradykinin evokes the endothelium-dependent relaxations in the presence of indomethacin and L-nitro-arginine (LNAG) in bovine coronary arteries (11).

In the present study, we determined if bovine coronary arteries release EDRFs other than nitric oxide in response to bradykinin using a sandwich-bioassay system. We also examined the effect of phorbol esters on the bradykinin-induced relaxation, because phorbol esters have been shown to inhibit the release of EDRFs (12, 13).

MATERIALS AND METHODS

Experiments were performed on left circumflex coronary arteries isolated from bovine hearts obtained from a nearby slaughterhouse. Coronary arteries were carefully dissected and cleaned of adhering connective tissue.

In the organ chamber experiment, the left circumflex coronary arteries were cut into 3- to 4-mm rings and mounted horizontally in organ chambers filled with 15 ml of Krebs-Ringer bicarbonate solution of the following composition: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl₂, 1.2 mM KH₂PO₄, 2.5 mM CaCl₂, 25 mM NaHCO₃, and 10 mM glucose. The chamber solution was maintained at 37°C and gassed with 95% O₂ and 5% CO₂. The coronary

* To whom correspondence should be addressed.
rings were attached to a force transducer, and isometric force was recorded. Each coronary ring was stretched to an optimal tension of 20 mN, as determined by repeated stimulation with 60 mM KCl. They were allowed to equilibrate for 90–120 min before starting the experiments.

In the bioassay experiment, two segments with endothelium were obtained from a circumflex coronary artery. They were cut into 9- to 10-mm rings and then opened. The opened circumflex coronary arteries (donor vessels) were fixed on a plastic board, as shown in Fig. 1. To detect released EDRFs from the donor vessels, a reversed ring of de-endothelialized left circumflex coronary artery (assay ring) was mounted in an organ chamber and contracted with prostaglandin F$_{2\alpha}$ (PGF$_{2\alpha}$) (3 x 10$^{-6}$ M). The isometric tension of the assay ring was measured by a force transducer. Donor vessels were transferred to the assay chamber, and then basal and bradykinin-induced release of EDRF from donor vessels was determined.

All experiments were performed in the presence of indomethacin (10$^{-5}$ M) to eliminate the effects of prostanoids (14).

The following drugs were used: bradykinin, LNAG, phorbol 12-myristate-13-acetate (PMA), 4-alpha-phorbol 12,13-didecanoate (4a-PDD), hemoglobin and d-arginine hydrochloride (Sigma Chemical Company, St. Louis, MO, USA); indomethacin, methylene blue and sodium nitroprusside (Nacalai Tesque, Inc., Kyoto); PGF$_{2\alpha}$ (Ono Pharmaceutical Co., Ltd., Osaka); L-arginine hydrochloride (Wako Pure Chemical Industries, Ltd., Inc., Osaka). PMA and 4a-PDD were dissolved in dimethylsulfoxide (final bath concentration of less than 0.1%). Oxyhemoglobin was prepared by adding a 10-fold excess of the reducing agent sodium dithionite to a 10$^{-3}$ M solution of commercial hemoglobin in distilled water. Sodium dithionite was then removed by dialysis five times against 100 volumes of distilled water for 4 hr at 4°C. Other drugs were dissolved in distilled water. The drugs were kept on ice during the experiments. Concentrations of the drugs are expressed as the final organ chamber concentrations (molar).

Results are expressed as means±S.E.M. In rings contracted with PGF$_{2\alpha}$, responses are expressed as a percentage of the relaxation induced by 10$^{-4}$ M papaverine. Unless stated otherwise, n refers to the number of animals. Statistical evaluation of the data was performed by Student's $t$-test for either paired or unpaired observations. When more than two mean values were compared, analysis of variance was used. If a significant F value was found, Scheffé's test for multiple comparisons was used to identify differences among groups. Values were considered to be statistically different when P was less than 0.05. The negative logarithm of the molar concentration of bradykinin causing 50% relaxation (EC$_{50}$) was calculated for each concentration-response curve, and the mean±S.E.M. of these values was presented.

RESULTS

Bradykinin evoked concentration-dependent relaxation in bovine coronary artery rings contracted with PGF$_{2\alpha}$.
As shown in Fig. 2, bradykinin-induced relaxations were not observed in de-endothelialized coronary rings, and they were little affected by oxyhemoglobin (10^{-5} M), but were significantly (P < 0.05) inhibited by methylene blue (10^{-5} M); however, relaxations were still present at about 60% of the maximal ones.

Four left circumflex coronary rings isolated from the same bovine heart were used in the next experiment. As shown in Fig. 3A, bradykinin (10^{-10} - 10^{-7} M) evoked concentration-dependent relaxation of an intact bovine coronary ring contracted with PGF_{2\alpha} (3 \times 10^{-6} M). Treatment of the coronary rings with LNAG (10^{-4} M) or PMA (10^{-7} M) had little effect on the endothelium-dependent relaxation induced by bradykinin (Fig. 3, B and C). Simultaneous application of LNAG and PMA almost completely abolished the bradykinin-induced endothelium-dependent relaxation in a coronary ring contracted with PGF_{2\alpha} (Fig. 3D). Results of the experiments are quantitatively summarized in Fig. 4. EC_{50} values for bradykinin were (1.15 \pm 0.15) \times 10^{-9} M in the control, (1.71 \pm 0.16) \times 10^{-9} M in the presence of LNAG (10^{-4} M), and (1.83 \pm 0.19) \times 10^{-9} M in the presence of PMA (10^{-7} M). There were no significant differences among these values. The maximal endothelium-dependent relaxation evoked by bradykinin was 69.5 \pm 5.4% in the control, 59.7 \pm 6.2% in the presence of LNAG and 70.7 \pm 5.3% in the presence of PMA. However, the maximal relaxation in the presence of both LNAG and PMA was 15.7 \pm 2.8%, which was significantly smaller than the other values.

Concentration-dependent effects of PMA on the bradykinin-induced endothelium-dependent relaxation and the bradykinin-induced LNAG-insensitive, endothelium-dependent relaxation are shown in Fig. 5 (A and B). At a higher concentration (10^{-6} M), PMA depressed 10^{-9} M and 10^{-8} M bradykinin-induced endothelium-dependent relaxations (Fig. 5A). On the other hand, at relatively lower concentrations (10^{-8} - 10^{-7} M), PMA inhibited the bradykinin-induced LNAG-insensitive, endothelium-dependent relaxation concentration-dependently (Fig. 5B). The inhibitory effect of a higher concentration (10^{-6} M) of PMA was not different from that of 10^{-7} M PMA (Fig. 5B). In contrast to PMA, 4a-PDD (10^{-7} M and 10^{-6} M) did not affect the LNAG-insensitive, endothelium-dependent relaxation evoked by bradykinin (Fig. 5C). PMA (10^{-7} M) showed no significant effects on the basal tension and PGF_{2\alpha}-induced contraction in
endothelium-intact rings (data not shown) and on the nitroprusside-induced relaxations in de-endothelialized rings. EC_{50} values for nitroprusside in the relaxation were \((3.55 \pm 0.29) \times 10^{-9} \text{ M}\) in the control and \((4.47 \pm 0.31) \times 10^{-9} \text{ M}\) in the presence of PMA \((10^{-7} \text{ M})\) \((n=6)\). There was no significant difference between these two values.

Both basal and bradykinin-induced releases of relaxing factor(s) were examined using sandwich preparations. As shown in Fig. 6A, transfer of donor vessels to the assay chamber resulted in a small relaxation which may be due to basal release of relaxing factor(s) from donor vessels. Addition of bradykinin \((10^{-9} - 10^{-7} \text{ M})\) relaxed the assay ring concentration-dependently. After treatment of donor vessels with LNAG \((10^{-4} \text{ M})\) for 30 min, neither of the relaxations was observed (Fig. 6B). In contrast, treatment of donor vessels with PMA \((10^{-7} \text{ M})\) for 30 min showed no significant effects on basal and bradykinin-induced relaxations (Fig. 6C). In addition, treatment of both donor and assay vessels with PMA \((10^{-7} \text{ M})\) for 30 min also showed no significant effects on basal and bradykinin-induced relaxations (data not shown).

Results of the experiments are quantitatively summarized in Fig. 7. LNAG \((10^{-4} \text{ M})\) almost completely prevented both basal and bradykinin-induced release of EDRFs from donor vessels. However, PMA \((10^{-7} \text{ M})\) showed no significant effect on basal and bradykinin-induced release from donor vessels. EC_{50} values for bradykinin were \((1.60 \pm 0.45) \times 10^{-9} \text{ M}\) in the control and \((4.12 \pm 1.31) \times 10^{-9} \text{ M}\) in the PMA-treated preparation. There was no

---

**Fig. 4.** Effects of l-nitro-arginine (LNAG) \((10^{-4} \text{ M})\) and/or phorbol 12-myristate-13-acetate (PMA) \((10^{-7} \text{ M})\) on bradykinin (BK)-induced endothelium-dependent relaxation in bovine coronary arteries. Coronary rings were contracted with prostaglandin F_{2\alpha} \((3 \times 10^{-8} \text{ M})\); the absolute contractions in controls ( ), LNAG ( ), PMA ( ), and their combined ( )-treated rings were 47.6±3.2 mN; 55.0±3.7 mN; 52.9±2.8 mN; and 51.2±4.0 mN, respectively. Relaxations induced by papaverine \((10^{-4} \text{ M})\) were taken as 100%. Each point represents the mean±S.E.M. of nine muscle strips from different animals. Combination of LNAG and PMA inhibited the relaxations induced by BK significantly (*P<0.05, **P<0.01).

---

**Fig. 5.** Effects of phorbol 12-myristate-13-acetate (PMA) and 4-alpha-porphol 12,13-didecanoate (4a-PDD) on bradykinin (BK)-induced endothelium-dependent relaxation in bovine coronary arteries. Experiments were performed in the absence of l-nitro-arginine (LNAG) (A) and in the presence of LNAG \((10^{-7} \text{ M})\) (B and C). In (A), control; ( ), LNAG \((10^{-4} \text{ M})\). In (B), control; ( ), PMA \((10^{-6} \text{ M})\); ( ), PMA \((3 \times 10^{-6} \text{ M})\); ( ), PMA \((10^{-7} \text{ M})\); ( ), PMA \((10^{-8} \text{ M})\). In (C), control; ( ), control; ( ), 4a-PDD \((10^{-6} \text{ M})\); ( ), 4a-PDD \((10^{-7} \text{ M})\). Coronary rings were contracted with prostaglandin F_{2\alpha} \((3 \times 10^{-8} \text{ M})\); the absolute contractions in controls (A), PMA \((10^{-4} \text{ M})\) (A)-treated rings, controls (B and C), PMA \((10^{-7} \text{ M})\) (B)- and 4a-PDD \((10^{-6} \text{ M})\) (C)-treated rings were 40.0±2.9 mN, 46.5±4.7 mN, 48.1±2.6 mN, 48.8±4.6 mN, and 46.6±3.9 mN, respectively. Relaxations induced by papaverine \((10^{-6} \text{ M})\) were taken as 100%. Each point represents the mean±S.E.M. of five to eight muscle strips from different animals. In the absence of LNAG (A), PMA \((10^{-8} \text{ M})\) significantly (*P<0.05, **P<0.01) inhibited BK-induced relaxation. In the presence of LNAG (B), PMA \((10^{-6} - 10^{-8} \text{ M})\) significantly (*P<0.05, **P<0.01) inhibited BK-induced relaxation, concentration-dependently.
significant difference between these two values. The maximal bradykinin-induced relaxation was 62.4 ± 5.90 in the control and 59.9 ± 4.8% in the PMA-treated preparation. There was no significant difference between these two values. However, the maximal relaxation in the preparation treated with LNAG was only 9.2 ± 5.90, which was significantly different from the other values.

Inhibitory effects of LNAG on basal and bradykinin-induced relaxations were almost reversed by treatment with L-arginine (9 × 10⁻³ M), but not with D-arginine (9 × 10⁻³ M) (Fig. 8). Treatment of the assay vessel with oxyhemoglobin (10⁻⁵ M) or methylene blue (10⁻⁵ M) completely abolished both basal and bradykinin (10⁻¹⁰ to 10⁻⁷ M)-induced relaxations (n = 5).

**DISCUSSION**

The present experiments showed that in isolated bovine coronary arteries, bradykinin evokes LNAG-insensitive, endothelium-dependent relaxation. This relaxation was in-

---

**Fig. 6.** Representative illustrations showing the effects of L-nitro-arginine (LNAG) (10⁻⁴ M) and/or phorbol 12-myristate-13-acetate (PMA) (10⁻⁷ M) on the release of endothelium-derived relaxing factors (EDRFs). (A) Relaxation of a bovine coronary artery (a denuded bioassay ring) in response to basal and bradykinin (BK)-induced release of EDRFs from the bovine coronary segments with endothelium (donor vessels). (B) Following exposure of donor vessels to LNAG (10⁻⁴ M) for 30 min, both basal and BK-induced relaxation of the assay ring was abolished. (C) Treatment of donor vessels with PMA (10⁻³ M) for 30 min affected neither the basal nor BK-induced relaxations of the assay ring. BK was added to the organ chamber at the indicated points; numbers indicate the cumulative concentration (−log M) of BK, and horizontal lines represent the level before the addition of prostaglandin F₂α (3 × 10⁻⁶ M). ↓, transfer of donor vessels to the assay chamber; PPV, papaverine (10⁻⁴ M).

**Fig. 7.** Effects of L-nitro-arginine (LNAG) (10⁻⁴ M) and/or phorbol 12-myristate-13-acetate (PMA) (10⁻⁷ M) on the release of endothelium-derived relaxing factors from donor vessels. Donor vessels with endothelium were treated with LNAG (10⁻⁴ M) (●) or with PMA (10⁻³ M) (□) for 30 min, and then basal (B) and bradykinin (BK)-induced relaxation were estimated. Relaxations induced by papaverine (10⁻⁴ M) were taken as 100%. Each point represents the mean ± S.E.M. of five experiments from different animals. *: LNAG significantly (P<0.05) inhibited the basal and BK-induced relaxations. ○: Control.

**Fig. 8.** Antagonizing effects of L-arginine and D-arginine on the inhibitory effect of L-nitro-arginine (LNAG). Donor vessels with endothelium were treated with LNAG (10⁻⁴ M) only (○) and together with L-arginine (△) or D-arginine (9 × 10⁻³ M) (□) for 30 min, and then basal (B) and bradykinin (BK)-induced relaxations were estimated. Relaxations induced by papaverine (10⁻⁴ M) were taken as 100%. Each point represents the mean ± S.E.M. of six experiments from different animals. *: L-arginine significantly (P<0.05) antagonized the inhibitory effect of LNAG. ●: Control.
hibited neither the basal release (Fig. 6C) nor the bradykinin-induced relaxation (Figs. 6C and 7). These results suggest that PMA might selectively inhibit the production or release of an EDRF different from nitric oxide.

The inhibitory effect of PMA may result from activation of protein kinase C in endothelial cells (24). In this study, 4α-PDD, which does not activate protein kinase C, did not affect the LNAG-insensitive, endothelium-dependent relaxation evoked by bradykinin. PMA did not influence the ability of the vascular smooth muscle to relax in response to nitroprusside which induced vascular smooth muscle relaxation by stimulation of soluble guanylate cyclase (25). Therefore, the observed inhibitory effect of PMA on LNAG-insensitive, endothelium-dependent relaxation may reflect an interruption of the signal transduction mechanisms in the endothelial cells. It has been reported that in canine coronary arteries, PMA (12) or phorbol 12,13-dibutyrate (13) evokes the endothelium-dependent contraction. However, PMA did not affect the basal tension of bovine coronary arteries with intact endothelium in this study. While the exact cause of species differences is unknown, it is tentatively speculated that a difference in the ratio of nitric oxide and non-nitric oxide factor(s) participating in endothelium-dependent mechanisms might contribute to it.

On the other hand, it has been reported that phorbol esters stimulate endothelial cells to release superoxide anions (26), which may cause nonspecific depression of endothelium-dependent relaxations by inhibiting the activity of endothelium-derived nitric oxide (27, 28). In the present experiments, the presence of PMA in the sandwich bioassay system did not influence the bradykinin-induced relaxations, suggesting that the inhibitory effect of PMA on LNAG-insensitive relaxation does not result from an increased release of superoxide. The results of the present study suggest that an increased activation of protein kinase C could be responsible for loss of bradykinin-induced LNAG-insensitive, endothelium-dependent relaxations of bovine coronary arteries.

It is concluded that in bovine coronary arteries, bradykinin releases nitric oxide and other endothelium-derived relaxing factor(s) which is an extremely labile substance(s) or a non-diffusible factor(s). These results together with evidence for the existence of endothelium-derived contractile and relaxing endothelins (29, 30) indicate the complex influence of the endothelium on vascular smooth muscle tone. Further studies on EDRFs other than nitric oxide are underway.

REFERENCES


